Drugs / 68Ga-JH12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06688188 | Nov 2024 → Jun 2025 overdue | cancer | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-JH12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06688188 ↗ |
| Modality | Diagnostic / imaging agent | “PET imaging” NCT06688188 ↗ |
| Route | Intravenous | “given intravenously.” NCT06688188 ↗ |
| Target | CXCR4 | “68Ga-JH12 is a novel radiotracer targeting C-X-C motif chemokine receptor 4 (CXCR4).” NCT06688188 ↗ |